[go: up one dir, main page]

MXPA03003151A - Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata. - Google Patents

Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.

Info

Publication number
MXPA03003151A
MXPA03003151A MXPA03003151A MXPA03003151A MXPA03003151A MX PA03003151 A MXPA03003151 A MX PA03003151A MX PA03003151 A MXPA03003151 A MX PA03003151A MX PA03003151 A MXPA03003151 A MX PA03003151A MX PA03003151 A MXPA03003151 A MX PA03003151A
Authority
MX
Mexico
Prior art keywords
prostate cancer
methods
compositions
select
modulators
Prior art date
Application number
MXPA03003151A
Other languages
English (en)
Inventor
Kurt C Gish
Original Assignee
Eos Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/847,046 external-priority patent/US20020068036A1/en
Application filed by Eos Biotechnology Inc filed Critical Eos Biotechnology Inc
Publication of MXPA03003151A publication Critical patent/MXPA03003151A/es

Links

Classifications

    • G01N33/57555—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MXPA03003151A 2000-10-13 2001-10-12 Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata. MXPA03003151A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US68757600A 2000-10-13 2000-10-13
US73328800A 2000-12-08 2000-12-08
US73374200A 2000-12-08 2000-12-08
US26395701P 2001-01-24 2001-01-24
US27679101P 2001-03-16 2001-03-16
US27688801P 2001-03-16 2001-03-16
US28192201P 2001-04-06 2001-04-06
US28621401P 2001-04-24 2001-04-24
US09/847,046 US20020068036A1 (en) 2000-10-13 2001-04-30 Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US28858901P 2001-05-04 2001-05-04
PCT/US2001/032045 WO2002030268A2 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Publications (1)

Publication Number Publication Date
MXPA03003151A true MXPA03003151A (es) 2003-08-19

Family

ID=27581207

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003151A MXPA03003151A (es) 2000-10-13 2001-10-12 Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.

Country Status (6)

Country Link
EP (1) EP1474528A4 (es)
JP (1) JP2005506033A (es)
AU (1) AU2002215345A1 (es)
CA (1) CA2425569A1 (es)
MX (1) MXPA03003151A (es)
WO (1) WO2002030268A2 (es)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008765B1 (en) 1997-04-10 2006-03-07 The Johns Hopkins University PCA3, PCA3 genes, and methods of use
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
CA2385477C (en) 1999-09-29 2009-11-03 Diagnocure Inc. Pca3 messenger rna species in benign and malignant prostate tissues
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
EP1366158B1 (en) * 2000-07-28 2008-05-21 Ulrich Wissenbach Trp8 markers for cancer
WO2002040716A2 (en) 2000-11-16 2002-05-23 Cemines, Llc Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
EP1356049A2 (en) * 2000-12-15 2003-10-29 Millennium Pharmaceuticals, Inc. Human sugar transporter proteins, potassium channel proteins, phospholipid transporter proteins and methods of use thereof
AU2002246708A1 (en) 2000-12-15 2002-08-12 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7081516B2 (en) 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
CA2439702A1 (en) * 2001-03-05 2002-09-19 Aventis Pharma S.A. Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR100788092B1 (ko) 2001-06-20 2007-12-21 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2458915A1 (en) 2001-08-31 2003-03-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer
EP1429793B1 (en) 2001-09-06 2015-02-25 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005519137A (ja) * 2001-09-17 2005-06-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ４６８２８ヒトアシル−ＣｏＡシンセターゼの使用方法
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
US20030175763A1 (en) * 2001-12-20 2003-09-18 Degenhardt Yan Y. Identification of an amplified gene and target for drug intervention
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
WO2005067629A2 (en) * 2004-01-06 2005-07-28 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
CA2485138C (en) 2002-05-10 2015-04-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth
DE10234901A1 (de) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
WO2004015108A1 (en) * 2002-08-09 2004-02-19 Melbourne Health Mammalian grainyhead transcription factors
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
WO2004018648A2 (en) * 2002-08-26 2004-03-04 Case Western Reserve University Methods for treating patients and identifying therapeutics
EP1573331A1 (en) * 2002-12-09 2005-09-14 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
JP2004357702A (ja) * 2003-05-09 2004-12-24 Research Association For Biotechnology 新規蛋白質およびそれをコードするｄｎａ
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
WO2005083086A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
PT1742966E (pt) 2004-04-22 2014-02-05 Agensys Inc Anticorpos e moléculas derivadas daí que se ligam às proteínas steap-1
WO2005106488A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
EP1794314A2 (en) * 2004-07-23 2007-06-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2006074914A2 (en) * 2005-01-13 2006-07-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Human rna helicase and therapeutic uses thereof
EP2325305B1 (en) 2005-02-25 2014-02-12 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
LT2845866T (lt) 2006-10-27 2017-07-10 Genentech, Inc. Antikūnai ir imunokonjugatai bei jų panaudojimas
DK2171090T3 (da) * 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
AU2008296927C1 (en) * 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
AU2014240339B2 (en) * 2007-10-25 2017-07-13 Toray Industries, Inc. Method for detection of cancer
JP5589274B2 (ja) * 2007-10-25 2014-09-17 東レ株式会社 免疫誘導剤
EP2207037B1 (en) * 2007-10-25 2016-09-07 Toray Industries, Inc. Method for detection of cancer
ES2532635T3 (es) 2008-07-15 2015-03-30 Genentech, Inc. Conjugados de antraciclina, proceso para su preparación y su uso como compuestos antitumorales
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
MA34277B1 (fr) 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
AU2011248354A1 (en) * 2010-05-03 2012-11-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
ES2567276T3 (es) 2011-05-12 2016-04-21 Genentech, Inc. Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
DK2750713T3 (en) 2011-10-14 2015-12-21 Medimmune Ltd PYRROLOBENZODIAZEPINS AND CONJUGATES THEREOF
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
KR101995621B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
JP6270859B2 (ja) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ ピロロベンゾジアゼピン−抗体結合体
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
JP5993093B2 (ja) 2012-10-12 2016-09-14 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン類およびその複合体
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
HK1216176A1 (zh) 2012-12-21 2016-10-21 Medlmmune Limited 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
AU2014229529B2 (en) 2013-03-13 2018-02-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014159981A2 (en) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2014144657A2 (en) * 2013-03-15 2014-09-18 Metamark Genetics, Inc. Compositions and methods for cancer prognosis
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
BR112016013861A2 (pt) 2013-12-16 2017-10-10 Genentech Inc conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
US20150252425A1 (en) * 2014-03-05 2015-09-10 Caldera Health Ltd. Gene expression profiling for the diagnosis of prostate cancer
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN121431692A (zh) 2016-03-25 2026-01-30 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HUE054689T2 (hu) 2017-02-08 2021-09-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
WO2018184966A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2020010305A1 (en) * 2018-07-05 2020-01-09 The Board Of Regents Of The University Of Oklahoma Gene signatures for cancer characterization and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
CN119215114A (zh) * 2024-12-03 2024-12-31 浙江理工大学 一种百合细胞外囊泡在制备肿瘤治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2292495A (en) * 1994-04-15 1995-11-10 Trustees Of Columbia University In The City Of New York, The Method for molecular staging of prostate cancer
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
EP1060266A4 (en) * 1998-02-23 2004-09-22 Dana Farber Cancer Inst Inc METHOD FOR IDENTIFYING REACTIVE SITES FOR GLYCOSYLASE FOR REPAIRING MISSING BASE PAIRS, ACTIVE SUBSTANCES AND USES THEREOF
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
CA2397407A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

Also Published As

Publication number Publication date
EP1474528A2 (en) 2004-11-10
EP1474528A4 (en) 2006-06-14
WO2002030268A3 (en) 2004-08-26
AU2002215345A1 (en) 2002-04-22
JP2005506033A (ja) 2005-03-03
WO2002030268A2 (en) 2002-04-18
CA2425569A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
MXPA03003151A (es) Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
DZ3415A1 (fr) Guanidinobenzamides comme mc4-r agonistes.
DE60137661D1 (de) Rauscharmer Reaktor mit niedrigem Verlust
BR0114264B1 (pt) cabo, e, composição polimérica.
ID30046A (id) Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin
BR0115810B1 (pt) composições cosméticas, dermatológicas e farmacêuticas isentas de tensoativos.
MX238203B (es) Tratamiento de semillas con combinaciones de piretrinas, piretroides y tlametoxam.
BR0007785B1 (pt) composiÇço em barra de limpeza de pele.
ES1049428Y (es) Aparato para validar tarjetas.
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
BR0012043B1 (pt) composiÇço de tratamento de cabelo.
EP1208232A4 (en) MARKERS FOR PROSTATE CANCER
AR025230A1 (es) Procedimiento para preparar fosfonometilglicina.
ES1046175Y (es) Tapon perfeccionado.
IT251783Y1 (it) Gruppi idraulici di miscelazione, da incasso.
ITMI20022028A1 (it) Fenton i.s.
ES1054581Y (es) Tapon de madera.
IT1318675B1 (it) Composizione cosmetica.
IT1318607B1 (it) Composizione cosmetica.
ITMI20031639A1 (it) Composizioni cosmetiche fotopretettrici ed abbronzanti.
ES1048044Y (es) Tapon trifuncional.
ES1047960Y (es) Mecanismo de freno y retencion para puertas elevables y similares, tal y como pueden ser seccionales.
ITRM20000040V0 (it) Easy playnet.
BR8002843Y1 (pt) disposiÇço introduzida em sutiç.
IT1301996B1 (it) Composizione cosmetica.